Baxter International Inc. finds its equity trading near annual lows as the medical technology company contends with a confluence of significant legal pressures and operational disruptions. Investors are grappling with whether there remains a viable path to recovery for the embattled firm.
Leadership Transition Amid Operational Headwinds
The company is navigating its current challenges amidst a key leadership change. In late October 2025, Heather Knight, who served as Executive Vice President and Chief Operating Officer, departed from Baxter. CEO Andrew Hider has assumed her responsibilities on an interim basis, adding to his workload during an already turbulent period for the organization.
Mounting Legal Liabilities from Infusion Pump Allegations
A central element of Baxter’s difficulties stems from escalating litigation concerning its Novum LVP infusion pump. The company faces numerous class-action lawsuits alleging systematic device failures. These legal actions contend that the pumps have malfunctioned through under-infusion, over-infusion, or complete cessation of fluid delivery, potentially exposing patients to severe injury risks.
The reported consequences are grave, with the device being linked to 79 serious injuries and two patient fatalities. In response to these issues, Baxter implemented a temporary halt on both deliveries and installations of the Novum LVP in July 2025. This product suspension directly impacts the recovery trajectory of the company’s hospital business segment.
Should investors sell immediately? Or is it worth buying Baxter?
Deteriorating Financial Performance
The operational setbacks have manifested clearly in the company’s financial results. While Baxter did post third-quarter 2025 revenue of $2.835 billion, this translated to a net loss of $46 million. This represents a dramatic reversal from the profit recorded during the same period last year.
Several concerning financial metrics have emerged:
* The company has revised its full-year 2025 operational revenue growth projection down to just 1-2%
* Share value has declined by 37.2% over the past twelve months
* The stock offers a dividend yield of 3.68%, but this comes with an unsustainable payout ratio of 307.69%
* Baxter currently shows a negative P/E ratio and reported a loss per share of -$0.70
These figures raise serious questions about the long-term viability of maintaining current dividend distributions.
Analyst Outlook Versus Market Reality
Despite the overwhelmingly negative current picture, market analysts maintain an average price target of $24.07 for Baxter shares. This suggests a potential upside of over 30% from current trading levels. The critical question for investors remains whether this optimistic projection can materialize given the substantial operational and legal hurdles the company must first overcome. The duration and ultimate cost of this challenging period for Baxter remain uncertain.
Ad
Baxter Stock: Buy or Sell?! New Baxter Analysis from January 2 delivers the answer:
The latest Baxter figures speak for themselves: Urgent action needed for Baxter investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 2.
Baxter: Buy or sell? Read more here...
